On this page

CUPRIC CHLORIDE

Prescription ANDA TE AP Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
CUPRIC CHLORIDE
Generic name
Cupric Chloride
Dosage form
Injection, Solution
Route
Intravenous
Marketing category
ANDA · ANDA
Labeler
Archis Pharma LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
5
Packages
7
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Cupric Chloride .4 mg/mL 204536 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intravenous
Presentations
12

Regulatory status

Source: Drugs@FDANDC Directory
Application number
217626
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 30, 2024
Sponsor
STIRA
Products on application
1
Submissions recorded
1
Products approved under application 217626.
Product Trade name Form Strength Ingredient Status TE Flags
217626-001 CUPRIC CHLORIDE INJECTABLE CUPRIC CHLORIDE Prescription AP

Therapeutic equivalence

Source: Orange Book
TE code
AP
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 217626.
Type No. Action Status Date Review
Original application 1 Approved April 30, 2024 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260204). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260204 HUMAN PRESCRIPTION DRUG · 20240926 HUMAN PRESCRIPTION DRUG · 20190516

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Cupric Chloride Injection, USP 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Cupric chloride injection contains 0.4 mg of copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage of copper is 0.3 mg/day to 0.5 mg/day. For pediatric patients, the suggested additive dosage of copper is 20 mcg/kg/day (0.05 mL/kg/day) up to a maximum of 500 mcg/day. This product is not appropriate for patients weighing less than 4 kg due to the inability to measure the appropriate amount of the product. Do not administer cupric chloride injection intramuscularly because the acidic pH of the solution may cause considerable tissue irritation. Cupric chloride injection should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. The solution contains no preservatives; discard the unused portion immediately after the admixture procedure is completed. Cupric chloride injection should be inspected visually for particulate matter and discoloration prior to administration. Do not use unless the solution is clear and the seal is intact. Cupric ion may degrade ascorbic acid in TPN solutions. In order to avoid this loss of ascorbate, multivitamin additives should be added to TPN solutions immediately prior to infusion. Alternatively, the multivitamin additive may be added to one container of TPN solution, followed by copper in a subsequent container.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Cupric chloride injection is contraindicated in patients with hypersensitivity to copper (see WARNINGS: Hypersensitivity Reactions ).

WARNINGS Hepatic Accumulation Copper is primarily eliminated in the bile and excretion is decreased in patients with cholestasis and/or cirrhosis. Hepatic accumulation of copper has been reported in autopsies of patients receiving long-term parenteral nutrition containing copper at dosages higher than recommended. Administration of copper to patients with cholestasis and/or cirrhosis may cause hepatic accumulation of copper. Administration of copper to patients with Wilson disease, an inborn error of copper metabolism with a defect in hepatocellular copper transport, may cause both increased hepatic accumulation of copper and aggravation of the underlying hepatocellular degeneration. For patients with cholestasis, biliary dysfunction, or cirrhosis, monitor hepatic and biliary function during long-term administration of cupric chloride injection. If a patient develops signs or symptoms of hepatobiliary disease during the use of cupric chloride injection, obtain serum concentrations of copper and ceruloplasmin and adjust the dose as indicated (see PRECAUTIONS: Hepatic Impairment ). Hypersensitivity Reactions Post-market safety reporting has identified copper hypersensitivity in women receiving copper-containing intrauterine devices, providing evidence that patients may experience hypersensitivity reactions when exposed to this metal. If hypersensitivity reactions (e.g., pruritis, angioedema, dyspnea, rash, urticaria) occur in patients receiving Cupric Chloride Injection in parenteral nutrition, discontinue the product and initiate appropriate medical treatment (see CONTRAINDICATIONS ). Aluminum Toxicity This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS None known.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Cupric ion may degrade ascorbic acid in total parenteral nutrition (TPN) solutions. In order to avoid this loss of ascorbate, multivitamin additives should be added to TPN solutions immediately prior to infusion. Alternatively, the multivitamin additive may be added to one container of TPN solution, followed by copper in a subsequent container.

Description

openFDA Drug Labeling

DESCRIPTION Cupric chloride injection USP, 0.4 mg/mL is a sterile, clear, colorless to light blue color, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 1.07 mg cupric chloride dihydrate; 9 mg sodium chloride and water for injection. The solution contains no bacteriostat, antimicrobial agent or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium hydroxide for pH adjustment. The osmolarity is 0.327 mOsmol/mL (calc.). Cupric chloride, USP is chemically designated cupric chloride, dihydrate. Its molecular weight is 170.48 g/mol. The molecular formula is CuCl 2 • 2H 2 O and the structural formula is: Cupric chloride, USP is a blue to blue-green crystalline compound freely soluble in water, soluble in alcohol and slightly soluble in ether. Sodium chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water. The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration. 1

OVERDOSAGE Acute copper toxicity has been reported in patients with oral, intravenous, or subcutaneous administration. Clinical manifestations included metallic taste, nausea, vomiting, diarrhea, abdominal pain, neurological signs, such as encephalopathy and multi-organ failure involving kidney, liver, blood and cardiovascular systems, which may be fatal. Chelating agents, such as D-penicillamine, can be used for treatment of acute toxicity. Long-term administration of parenteral copper above the recommended dosage may result in significant accumulation of copper in the liver, brain and other tissues with possible organ damage (see WARNINGS: Hepatic Accumulation ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Cupric Chloride Injection, USP 0.4 mg/mL is supplied as follows: NDC 72603-351-01 10 mL Single-dose glass vial NDC 72603-351-25 Carton of 25 x 10 mL Single-dose glass vials Storage : Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Immacule Lifesciences Private Limited Village Thanthewal, Ropar Rd, Nalagarh Solan District, HP 174101, India To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Iss. 07/2024 PI-CUC-00-NS LEIA-311.00 10573

Adverse event reports

Source: openFDA FAERS
730
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CUPRIC CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
80830-2301-5 80830-2301 Amneal Pharmaceuticals Private Limited 25 VIAL in 1 CARTON (80830-2301-5) / 10 mL in 1 VIAL (80830-2301-1) January 29, 2026
72819-234-16 72819-234 Archis Pharma LLC 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72819-234-16) / 10 mL in 1 VIAL, SINGLE-DOSE (72819-234-06) July 5, 2024
72819-234-99 72819-234 Archis Pharma LLC 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72819-234-99) / 10 mL in 1 VIAL, SINGLE-DOSE (72819-234-96) October 1, 2024
51754-0103-3 51754-0103 Exela Pharma Sciences, LLC 10 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-3) / 10 mL in 1 VIAL, SINGLE-DOSE February 1, 2023
51754-0103-4 51754-0103 Exela Pharma Sciences, LLC 25 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-4) / 10 mL in 1 VIAL, SINGLE-DOSE February 1, 2023
72603-351-25 72603-351 Northstar Rx LLC 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72603-351-25) / 10 mL in 1 VIAL, SINGLE-DOSE (72603-351-01) October 1, 2024
84897-013-25 84897-013 Renova Pharmaceuticals LLC 25 VIAL, SINGLE-DOSE in 1 PACKAGE (84897-013-25) / 10 mL in 1 VIAL, SINGLE-DOSE (84897-013-01) May 7, 2026
80830-2301 80830-2301 Amneal Pharmaceuticals Private Limited — January 29, 2026
72819-234 72819-234 Archis Pharma LLC — July 5, 2024
51754-0103 51754-0103 Exela Pharma Sciences, LLC — February 1, 2023
72603-351 72603-351 Northstar Rx LLC — October 1, 2024
84897-013 84897-013 Renova Pharmaceuticals LLC — May 7, 2026

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 10 sections on this page.